Accepted answer
Week 7 is day 49: on a four-week ladder that is week 3 of dose step 2, and — at the seven-day half-life this class runs on — 7 half-lives in. Steady state is about five half-lives, so day 35 is where the concentration stops climbing on its own. Day 49 is 2 weeks past it, which means the level is no longer the variable. That distinction is most of the question: at week 3 of a step, an effect that is still accumulating is indistinguishable from one that is not resolving unless you know which side of day 35 you are on. Dizziness in a deficit is usually postural and usually volume-related. It is also the symptom on this list with the shortest path to something that needs assessing in person rather than posting about. Dose decisions are made under supervision, and nothing here is medical advice.
Answer first: the titration schedule exists to let tolerance to the gastrointestinal effects develop between steps, and every step in it is a tolerability decision rather than an efficacy one.
For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.
The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.
Titration schedules in the licensed products were designed specifically to manage gastrointestinal tolerability, and that intent is stated in the clinical development literature.
The caveat is that titration decisions belong with a clinician who knows what else is on board.
Stepping back is a normal adjustment, not a failure.
6Same experience here, different supplier. – vial_five 4 months ago add a comment